Sign in

    Bonnie Quach

    Research Analyst at Stifel Financial Corp.

    Bonnie Quach is an Equity Research Associate at Stifel Financial Corp., specializing in life sciences and healthcare sector analysis. She has directly covered companies such as MEI Pharma, participating in earnings calls and assisting with in-depth company research and investor communication. Since joining Stifel, Quach has contributed to the research team’s coverage of emerging biopharmaceutical firms, following earlier foundational roles in equity research. She holds FINRA registration and maintains relevant securities licenses, underscoring her compliance and expertise in financial analysis and client service.

    Bonnie Quach's questions to Lite Strategy (MEIP) leadership

    Bonnie Quach's questions to Lite Strategy (MEIP) leadership • Q4 2021

    Question

    Bonnie Quach of Stifel Financial Corp. inquired about the upcoming top-line data for the TIDAL study, asking what to expect regarding follow-up duration, the analysis of POD24 patients, and the rationale for selecting relapsed/refractory colorectal cancer (CRC) for the ME-344 trial.

    Answer

    Dan Gold, President and CEO, explained that the primary endpoint for the TIDAL readout is overall response rate (ORR) after a minimum of 6 months of treatment, with more precise durability data expected in the first half of the next year. He confirmed POD24 patients are being analyzed as an exploratory endpoint. For ME-344, the choice of third-line CRC was based on an advisory panel's consensus that it is a setting where Avastin is used but has low efficacy, presenting a clear opportunity to demonstrate improved patient outcomes.

    Ask Fintool Equity Research AI